Oncología Traslacional
ONCTRAS
Institute Catalá Oncología
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Institute Catalá Oncología (24)
2024
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Journal of Clinical Oncology
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma
Journal of Personalized Medicine, Vol. 14, Núm. 2
2023
-
Prognostic factors in patients with uterine sarcoma: The SARCUT study
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial
Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502
-
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO Open, Vol. 7, Núm. 5
-
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
Journal of Personalized Medicine, Vol. 12, Núm. 11
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
2020
-
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282
2019
-
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer
International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 1050-1056
-
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
A novel epigenetic signature for early diagnosis in lung cancer
Clinical Cancer Research, Vol. 22, Núm. 13, pp. 3361-3371
-
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525
-
SEOM Clinical Guideline in ovarian cancer (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1206-1212